Skip to main content
APRE logo

Aprea Therapeutics, Inc.

APRENASDAQHealthcareBiotechnology

$0.58Today:- (-)1Y −60.66%

As of Oct 16, 2026 close

Market cap
$33.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.55$1.69
Volume (live)
-
Avg. volume (3M)
216.78K

Aprea Therapeutics (APRE) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Aprea Therapeutics used $12.89M of cash in operating activities. Free cash flow was −$12.89M.

Aprea Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Aprea Therapeutics, Inc. (APRE) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-12.60-12.96-14.29-112.66-37.13-53.48-28.06-15.53-15.19
Depreciation & Amortization0.020.020.010.190.270.230.170.010.01
Stock Based Compensation0.480.490.4416.987.814.981.350.330.40
Change in Working Capital-0.93-1.061.62-1.76-8.335.571.160.901.45
Change in Accounts Payable-0.65-0.310.83-0.86-2.732.330.440.210.33
Change in Other Working Capital-0.280.020.79-0.90-0.383.250.730.691.12
Other Operating Activities0.130.020.0472.24-0.320.89-1.33-0.96-0.66
Net Cash from Operating Activities-12.89-13.56-12.18-25.01-37.69-41.80-26.71-15.25-14.00
Investing Activities
Capital Expenditures0.00-0.02-0.090.000.00-0.03-0.030.000.00
Net Cash from Investing Activities0.00-0.02-0.090.000.00-0.03-0.030.000.00
Financing Activities
Common Stock Issued4.6416.145.790.681.750.1586.9156.3723.34
Other Financing Activities0.00-1.32-0.650.000.210.005.6756.3723.34
Net Cash from Financing Activities4.6414.825.140.681.750.1592.5856.3723.34
Summary
Effect of Forex Changes on Cash0.00-0.01-0.010.040.000.61-1.420.161.39
Net Change in Cash-8.251.25-7.14-24.29-35.94-41.0764.4141.2710.74
Cash at Beginning of Period22.8921.6528.7953.0889.02130.0965.6824.4013.67
Cash at End of Period14.6422.8921.6528.7953.0889.02130.0965.6824.40
Free Cash Flow-12.89-13.57-12.27-25.01-37.69-41.83-26.74-15.25-14.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Aprea Therapeutics Cash Flow

What is Aprea Therapeutics's free cash flow?

Aprea Therapeutics had negative free cash flow of $12.89M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Aprea Therapeutics pay dividends or buy back shares?

Aprea Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition